| Your child will receive the best medical care available from our staff of caring, committed professionals. The clinicians at Legacy Pediatrics are nationally recognized for their research involving childhood diseases and care.
is Clinical Associate Professor of Pediatrics at the University of Rochester in Rochester, New York. Dr. Casey received her undergraduate degree from Stanford University followed by her medical degree from Case Western Reserve University School of Medicine. She completed her postgraduate pediatric residency at the University of Washington in Seattle, followed by a fellowship in Pediatric Hematology-Oncology at Duke University with emphasis in infectious diseases of the immunocompromised host.
Dr. Casey is a partner at Legacy Pediatrics where she practices primary care and as a sub specialist consultant. Dr. Casey is the co-director of research at Legacy Pediatrics where she acts as Principle Investigator for many clinical research grants. She has published numerous articles and chapters on ambulatory pediatric infectious disease topics. Her major practice and research interests are in otitis media, streptococcal infections, lower respiratory infections, and vaccine development.
was a member of the discovery team at the University of Rochester that invented, tested and licensed a Haemophilus influenzae b (Hib) conjugate vaccine (HibTITER®) now universally given to children in the U.S. This “conjugate” vaccine technology was used in the subsequent development of another universally-given vaccine- the pnuemococcal conjugate vaccine (Prevnar®). Dr. Pichichero has played a role in the clinical and/or translational research leading to licensure of many vaccines including acellular pertussis vaccines (DTaP), combination vaccines (DTaP-Hib-polio and DTaP-Hepatitis B-polio), meningococcal conjugate vaccine, Rotavirus vaccine, Human papillomavirus vaccine, adolescent Tdap vaccines and others.
Now Dr. Pichichero is leading a research team of scientists at Rochester General Hospital working toward the development of a multi-component vaccine to prevent ear, sinus and lung infections caused by pneumococci and non-typeable H. influenzae. The approach is multi-focused including:
1. The study of natural infection and asymptomatic colonization with these bacteria in children.
2. Evaluation of serum and mucosal antibody; generation of B memory cell and T cell responses to disease, colonization and vaccine candidates.
3. Molecular epidemiology.
4. Vaccine antigen discovery.
The Pichichero lab also collaborates with vaccine companies, international scientists, federally funded investigators, the NIH, FDA, CDC and WHO to characterize immunogenicity and efficacy of vaccines. |
